These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12591377)

  • 21. Optimization of cyclosporine exposure utilizing C(2) level monitoring in de novo renal transplant recipients: the Toronto General Hospital experience.
    Maham N; Cardella C; Cattran D; Fenton S; O'Grady C; Hamill J; Smith R; Cole E
    Transplant Proc; 2001; 33(7-8):3098-9. PubMed ID: 11750331
    [No Abstract]   [Full Text] [Related]  

  • 22. Plasma endothelin in cyclosporine A-treated renal transplant patients.
    Grekas D; Bamichas G; Karamouzis M; Bacharaki D; Savidis N; Tourkantonis A
    Transplant Proc; 1999 May; 31(3):1703-5. PubMed ID: 10331044
    [No Abstract]   [Full Text] [Related]  

  • 23. Changes in urinary interleukin-2 in kidney transplant recipients.
    Kumano K; Irie A; Mashimo S; Endo T; Koshiba K
    Transplant Proc; 1996 Jun; 28(3):1248-9. PubMed ID: 8658644
    [No Abstract]   [Full Text] [Related]  

  • 24. Study of neoral kinetics in adult renal transplantation treated with diltiazem.
    Mezzano S; Flores C; Ardiles L; Foradori A; Elberg A
    Transplant Proc; 1998 Aug; 30(5):1660-2. PubMed ID: 9723232
    [No Abstract]   [Full Text] [Related]  

  • 25. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation.
    Yussim A; Shaharabani E; Mor E; Lustig S; Bar-Nathan N; Shmueli D; Sobolev V; Dorfman B; Or H; Shapira Z
    Transplant Proc; 1996 Dec; 28(6):3178-9. PubMed ID: 8962233
    [No Abstract]   [Full Text] [Related]  

  • 26. Three-hour postdose cyclosporine level monitoring: less rejection and more nephrotoxicity?
    Domínguez J; Tomic A; Norambuena R
    Transplant Proc; 2001; 33(7-8):3120-1. PubMed ID: 11750341
    [No Abstract]   [Full Text] [Related]  

  • 27. Optimizing Neoral therapeutic drug monitoring with cyclosporine trough (C(0)) and C(2) concentrations in stable renal allograft recipients.
    Einecke G; Mai I; Diekmann F; Fritsche L; Boehler T; Neumayer HH; Budde K
    Transplant Proc; 2001; 33(7-8):3102-3. PubMed ID: 11750333
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of calcium channel blockers in renal allograft patients receiving cyclosporine.
    Suh BY; Kwun OS; Kwun KB
    Transplant Proc; 1998 Nov; 30(7):3558-60. PubMed ID: 9838558
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy and safety of changing from cyclosporine C0 to C2 monitoring in stable recipients following renal transplantation: a prospective cohort study.
    Zhang Y; Zhang XD; Wang Y
    Transplant Proc; 2011 Dec; 43(10):3697-701. PubMed ID: 22172829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Area under the curve of Neoral and chronic use of mycophenolate mofetil.
    Rial M; Guardia O; Greco G; Argento J; Casadei D
    Transplant Proc; 1998 Jun; 30(4):1195-6. PubMed ID: 9636484
    [No Abstract]   [Full Text] [Related]  

  • 31. Variability of Sandimmune pharmacokinetics in renal transplant patients.
    Wingerchuk C; Heim-Duthoy KL; Macres MG; Kasiske BL
    Transplant Proc; 1998 Aug; 30(5):1656-7. PubMed ID: 9723230
    [No Abstract]   [Full Text] [Related]  

  • 32. Convenience of level of cyclosporine-Neoral at time 3 to determine the area under curve in renal transplant.
    Rial MC; Frias S; Argento J; Tessler J; Casadei D
    Transplant Proc; 1997; 29(1-2):292-3. PubMed ID: 9123001
    [No Abstract]   [Full Text] [Related]  

  • 33. Cyclosporine therapy in pancreas transplantation.
    Davidson I; Lu C; Melone D; Risser R
    Transplant Proc; 1996 Aug; 28(4):2134-5. PubMed ID: 8769179
    [No Abstract]   [Full Text] [Related]  

  • 34. Conversion from cyclosporine to tacrolimus prevents transplant function loss due to acute steroid-resistant or chronic rejection in renal allograft recipients.
    Blume C; Hollenbeck M; Ivens K; Heering P; Hetzel GR; Grabensee B
    Transplant Proc; 2001; 33(7-8):3161-3. PubMed ID: 11750357
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of conversion from cyclosporine to tacrolimus on lipid profiles in renal transplant recipients.
    Colak T; Karakayali H; Yagmurdur MC; Moray G
    Transplant Proc; 2002 Sep; 34(6):2081-2. PubMed ID: 12270321
    [No Abstract]   [Full Text] [Related]  

  • 36. Low exposure to cyclosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation.
    Citterio F; Torricelli P; Serino F; Foco M; Pozzetto U; Fioravanti P; Castagneto M
    Transplant Proc; 1998 Aug; 30(5):1688-90. PubMed ID: 9723245
    [No Abstract]   [Full Text] [Related]  

  • 37. Safety, tolerability, and pharmacokinetics of Sandimmun Neoral: conversion study in stable renal transplant recipients.
    Tsang WK; Ho YW; Tong KL; Chan WH; Chan A
    Transplant Proc; 1996 Jun; 28(3):1330-2. PubMed ID: 8658681
    [No Abstract]   [Full Text] [Related]  

  • 38. Long-term experience with Sandimmun Neoral: results in de novo and stable renal transplant patients after 24-month treatment. The German Neoral Study Group.
    Korn A; Färber L; Maibücher A; Buchholz B; Offermann G
    Transplant Proc; 1997 Nov; 29(7):2945-7. PubMed ID: 9365623
    [No Abstract]   [Full Text] [Related]  

  • 39. Neoral reduces the incidence of acute rejection after renal transplantation.
    Sandrini S; Setti G; Gaggia P; Chiappini R; Maffeis R; Tardanico R; Maiorca R
    Transplant Proc; 1998 Aug; 30(5):1758-9. PubMed ID: 9723269
    [No Abstract]   [Full Text] [Related]  

  • 40. Abbreviated cyclosporine pharmacokinetic profiling in clinical renal transplantation: from principles to practice.
    Vathsala A; Lu YM
    Transplant Proc; 2001; 33(7-8):3137-9. PubMed ID: 11750348
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.